Trial
NCT05442775
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Cytokinetics
Collaborators
—
Condition
Amyotrophic Lateral Sclerosis
Intervention
Reldesemtiv
Why stopped
The DMC recommended the trial be discontinued due to futility following a planned second interim analysis of the parent trial (CY 5031).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-13